Benefit and safety of capecitabine after resection of biliary tract cancer: a real-world study with propensity score matching
{{output}}
Biliary tract cancer (BTC) is a high mortality disease, with few patients eligible for resection. Even post-surgery, recurrence rates remain high. The benefit of capecitabine as adjuvant therapy is uncertain, as seen in the BILCAP trial results. This study aim... ...
